In 62 patients with early-stage thyroid cancer, BRAFV600E, RET, NRAS and TERTp mutations were not detected in ctDNA using qPCR; however, one healthy control (1.9%) harboured a KRAS mutation in their plasma sample [68]. This evidence concerns the gene RET and thyroid cancer.